Topic

Angie Drakulich was editorial director of Pharmaceutical Technology.

Articles

As part of the BRIC bloc with Russia, India, and China, Brazil is one of the world's leading emerging economies and is also considered by IMS Health to be one of seven pharmerging nations, which also include Mexico, Turkey, and South Korea.

Global Healthcare on the Ground: Brazil's Development Bank Leader Discusses the Country's Pharma Future

Sean Milmo is a freelance writer based in Essex, UK.

The European Union market takes steps toward continuous processing and modular facilities.

Report from Europe

Nathan Jessop is a columnist for Pharmaceutical Technology Europe.

The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales.

European Pharma Companies Set To Surge Ahead Of US Rivals

Cultivating a productive investment environment will require partnerships with a range of stakeholders.

Global Healthcare on the Ground: USAID Works to Carry out President Obama's Global Health Initiative

Jane Wan is a freelance writer based in Singapore.

Packaging is indeed headed to be a lead sector in the Asian pharmaceutical environment, but certain challenges must first be overcome.

Report from Asia

Novartis AG and Novartis Pharmaceuticals Corporation have been focusing research efforts on rare diseases since the company was established in 1996.

Global Healthcare on the Ground: Novartis Focuses on Treating Rare Diseases

Russia is aiming to provide an alternative to China and India for drug manufacturing, including APIs.

Report from Russia

AAPS Global Health Focus Group's Kishor M. Wasan discusses new initiatives.

Global Healthcare on the Ground: AAPS on Why Global HealthCare is Important Now

In an effort to balance bilateral trade, India is urging China to increase Indian pharmaceutical imports.

Report from India

Electronic prescribing has grown strongly in the US but its future as a European-wide approach in healthcare has been uncertain; new regulatory interest could change the playing field.

Global Perspectives